32.59 USD
↘ 0.46 (1.38%)LIVE (AS OF 02:52 PM EDT)
Zenas BioPharma, Inc. Common Stock
ZBIONASDAQ • USD
Market: OPEN
Zenas BioPharma, Inc. Common Stock (ZBIO) trades at $32.59 per share. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Sell. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Furthermore, ZBIO is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Aug 26, 2026.
Open?$32.81
High?$33.63
Low?$32.45
Prev. Close?$33.04
Volume?368.4K
Avg. Volume?775.4K
VWAP?$33.10
Rel. Volume?0.48x
Bid / Ask
Bid?$32.49 × 100
Ask?$32.68 × 100
Spread?$0.19
Midpoint?$32.59
Valuation & Ratios
Market Cap?2.2B
Shares Out?65.2M
Float?29.1M
Float %?46.2%
P/E Ratio?N/A
P/B Ratio?8.71
EPS?-$7.43
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Employees
167
Market Cap
2.2B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2024-09-13
Address
852 WINTER STREET, SUITE 250
WALTHAM, MA 02451
Phone: 857-271-2954
WALTHAM, MA 02451
Phone: 857-271-2954
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?2
Momentum?50
Short Sent.?30
Piotroski F-Score?0/9Weak
Altman Z-Score?-0.30Distress
Confidence?57%Low
Short InterestSqueeze Risk
Short % of Float?40.00%Squeeze Risk
Short Interest?11.7M
Days to Cover?21.1
Free Float29.1M
Avg Daily Volume553.7K
Settlement Date2026-08-14
Financial Health
Current Ratio?9.93Strong
Quick Ratio?9.93Strong
Cash Ratio?2.99Strong
Debt/Equity?1.20Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score50/100
P/E?N/A▾
P/B?8.71HIGH▾
Peers100
S&P22
P/S?2,153.44HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-4.7CHEAP▾
S&P97
EV/Sales?2,253.88HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-196.0%WEAK▾
S&P3
ROA?-69.0%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-225974000
Enterprise Value?$2.3B
Fundamentals ratios updated end of day